References in periodicals archive ?
Analysis of these hematologic parameters suggested that the pattern of beneficial effects of ICA-17043 observed during the Phase II study were maintained during the open label study.
The study is a Phase I/II dose-escalating, multi-center, non-comparative, open label study designed to assess the safety and the efficacy of Defibrotide with MPT regimen as a salvage treatment in advanced refractory MM patients.
Data from this 16-week open label study, led by Ira Shafran, MD, of the Shafran Gastroenterology Center, show that at the end of treatment 78 percent of study participants had a greater than 70 percent improvement in Crohn's Disease Activity Index (CDAI), and that 59 percent achieved clinical remission, defined as a CDAI score of less than 150.
An open label study is being conducted to assess the safety of chronic exposure to Neurodex in patients with PBA associated with various neurological disorders including ALS, MS, stroke, Alzheimer's disease, Parkinson's disease, and traumatic brain injury.

Full browser ?